iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) logo

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (OM3E)

Market Closed
14 Aug, 20:00
XMUN XMUN
8. 54
-0.12
-1.4086%
- Market Cap
- Div Yield
2,500 Volume
8.66
Previous Close
Add Transaction
Day Range
8.54 8.55
Year Range
5.69 8.67
Want to track OM3E and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

OM3E closed Friday lower at €8.54, a decrease of -1.4086% from Thursday's close, completing a monthly increase of 2.6692% or €0.22. Over the past 12 months, OM3E stock gained 21.2065%.
OM3E pays dividends to its shareholders, with the most recent payment made on Jun 30, 2026. The next estimated payment will be in In 4 months on Dec 30, 2026 for a total of €0.011.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on LSE (USD).

OM3E Chart

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (OM3E) FAQ

What is the stock price today?

The current price is €8.54.

On which exchange is it traded?

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) is listed on XMUN.

What is its stock symbol?

The ticker symbol is OM3E.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) ever had a stock split?

No, there has never been a stock split.

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) Profile

XMUN Exchange
US Country

Overview

Canopus BioPharma Incorporated is a pharmaceutical research company with a focus on providing innovative pharmaceutical products and assay methods for patients suffering from infectious diseases, cancer, and addictions. Originally founded in 1996 as Canopus Corporation, the company underwent a name change in 2007 to better reflect its dedication to the field of biopharmaceuticals. Headquartered in Santa Monica, California, Canopus BioPharma Incorporated is committed to developing solutions that address the urgent needs of patients worldwide through extensive research and development efforts.

Products and Services

  • Antivirals: These products are designed to combat various viral infections, providing crucial options for treatment in the fight against persistent and emerging viral diseases.
  • Radiation Protection Products: Aimed at protecting individuals from the harmful effects of radiation, these products are essential for both medical treatments requiring radiation and for protection in environments with elevated radiation levels.
  • Oncology Products: Focusing on the treatment of cancer, this range includes therapies and supportive care products designed to target cancer cells while minimizing side effects, thereby improving patient outcomes.
  • Bio-barcode Assays: Innovative diagnostic tools that allow for the ultra-sensitive detection of various biomolecules. These assays play a significant role in early disease detection and monitoring, thereby enhancing treatment strategies.
  • Camelidae Blood Products: Utilizing the unique antibodies found in the blood of camels and their relatives, these products offer promising options for the development of treatments and diagnostics in a range of diseases, leveraging the distinct advantages of camelid antibodies.
  • Neutraceuticals: These health-enhancing products bridge the gap between pharmaceuticals and nutrition, offering dietary supplements designed to support overall health and complement traditional therapeutics.

Contact Information

Address: 233 Wilshire Boulevard, Santa Monica, CA, United States, 90401
Phone: 353-627-8674